1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Astellas Pharma Inc
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Aurinia Pharmaceuticals Inc.
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Bristol-Myers Squibb
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. ChemoCentryx, Inc.
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Complexa
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Dimerix
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. Goldfinch Biopharma Inc.
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. GlaxoSmith Kline
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Kyowa Hakko Kirin
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Ligand Pharmaceuticals
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. Oraxion Therapeutics
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. Pfizer
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Reata Pharmaceuticals, Inc.
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.14. Retrophin, Inc.
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. Silver Creek Pharmaceuticals, Inc.
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. TRISAQ Inc.
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.17. Variant Pharmaceuticals, Inc.
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.18. Vifor Pharma
6.18.1. Introduction
6.18.2. Financials
6.18.3. Products and Services
6.18.4. SWOT
List of Tables
List of Figures